Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232104 | 0.83 | KMT2A (0.68) | ALDH1A1KMT2AKDM4EHSD17B10HPGD | |
| SCHEMBL7032067 | 0.80 | ALDH1A1 (0.71) | ALDH1A1KMT2APSMB5KDM4EHPGD | |
| SCHEMBL27388643 | 0.79 | KMT2A (0.51) | ALDH1A1KMT2AKDM4EPPARG | |
| SCHEMBL14397981 | 0.79 | ALDH1A1 (0.73) | ALDH1A1KMT2APSMB5HPGDHTT | |
| SCHEMBL11883414 | 0.79 | ALDH1A1 (0.73) | ALDH1A1KMT2APSMB5HPGDHTT | |
| SCHEMBL10814639 | 0.77 | ALDH1A1 (1.00) | ALDH1A1KMT2APSMB5HPGDHTT | |
| SCHEMBL31541283 | 0.77 | ALDH1A1 (1.00) | ALDH1A1KMT2APSMB5HPGDHTT | |
| SCHEMBL8672570 | 0.77 | ALDH1A1 (0.71) | ALDH1A1KMT2APSMB5HPGDHTT | |
| SCHEMBL11458326 | 0.77 | ALDH1A1 (0.71) | ALDH1A1KMT2APSMB5KDM4EHPGD | |
| SCHEMBL29485041 | 0.77 | ALDH1A1 (0.71) | ALDH1A1KMT2APSMB5HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657228-B2 | Performance boosting UV-absorbing compounds | ISP INVESTMENTS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657228-B2 | Performance boosting UV-absorbing compounds | ISP INVESTMENTS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140023601-A1 | PERFORMANCE BOOSTING UV-ABSORBING COMPOUNDS | ISP INVESTMENT INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140023601-A1 | PERFORMANCE BOOSTING UV-ABSORBING COMPOUNDS | ISP INVESTMENT INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8557226-B2 | Performance-boosting UV-absorbing compounds | ISP INVESTMENTS INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557226-B2 | Performance-boosting UV-absorbing compounds | ISP INVESTMENTS INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100183532-A1 | Performance-Boosting UV-Absorbing Compounds | HERCULES LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100183532-A1 | Performance-Boosting UV-Absorbing Compounds | HERCULES LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183532-A1 | Performance-Boosting UV-Absorbing Compounds | APOB, ALOX5, RARG | ALDH1A1 118/4885KMT2A 4151/4885PSMB5 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.